STOCK TITAN

INTL STEM CELL CORP - $ISCO STOCK NEWS

Welcome to our dedicated page for INTL STEM CELL news (Ticker: $ISCO), a resource for investors and traders seeking the latest updates and insights on INTL STEM CELL stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INTL STEM CELL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INTL STEM CELL's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
91.43%
Tags
INTL STEM CELL CORP

OTC:ISCO

ISCO Rankings

ISCO Stock Data

960.53k
3.70M
53.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
San Diego

About ISCO

international stem cell corporation (otcbb:isco) develops a powerful new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection. parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpsc) that can be “immune-matched” to millions of persons of differing sexes and racial backgrounds. a relatively small number of hpsc lines could provide sufficient immune-matched cells to cover large parts of the world’s population. isco plans to create a bank of these valuable hpsc lines (unistemcell™) to serve all populations across the world. human parthenogenetic stem cells have great therapeutic potential, yet do not require viable human embryos, thus avoiding ethical issues. isco’s scientists are focused on using hpsc to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven clinically yet is limi